This was a randomized phase III clinical study evaluating the epigenetic inactivation of the MGMT gene as a predictive factor for benefit from adjuvant treatment with temozolomide plus radiotherapy compared with radiotherapy alone in patients with newly diagnosed glioblastoma multiforme (GBM). This evidence concerns the gene MGMT and glioblastoma.